Celtic Pharma Holdings Appoints Dr. Andy Richards to its Advisory Board
Celtic Pharma Holdings Advisors LLP, the advisor to the second Celtic Pharma fund, Celtic Pharma Holdings II LP), announced it has appointed Dr. Andy Richards to its Advisory Board.
Dr. Richards is one of the UK’s biotechnology entrepreneurs with a strong track record of founding, investing in, and developing high growth biotechnology and healthcare companies. In the past ten years, he has played a key role in growing the value and generating significant returns for investors in a large number of UK biotechnology companies. Dr. Richards has also advised the UK Government’s Office of Life Sciences, which is led by the Minister for Science and Innovation Lord Drayson, and UK Trade & Investment on biotechnology issues.
He is currently Chairman of Altacor Ltd and Novacta Biosciences Ltd, and a non-executive director of Vectura Group plc, Summit Corp. plc, Biowisdom Ltd, Babraham Bioscience Technology Ltd , Cancer Research Technology Ltd (commercial arm of CR-UK), and Arecor Ltd. He is also founder member of the Cambridge Angels, a director of the UK Bioindustry Association (BIA) and a member of Biotechnology and Biological Sciences Research Council (BBSRC).
Dr. Richards spent his early career with ICI plc (now AstraZeneca plc) and with PA Technology. In 1992, he co-founded Chiroscience, one of Europe’s most successful biotech companies, and was business development director through to the merger in 1999 with Celltech (now UCB).
Dr. Richards has a track record in successful biotechnology exits having been a founder and director of Arakis Ltd, which was acquired by Sosei in 2005, Cambridge BioTechnology Ltd, acquired by Biovitrum in 2005, and PharmaKodex Ltd, acquired by Orexo in 2009.
Other news from the department people
